MYOD1 mutation drives cancer stem cell pathways and therapy-resistance in spindle cell/sclerosing rhabdomyosarcoma
3d ago1 min readNews
From the article
Discover the power of mutation: MYOD1 L122R boosts cancer stem cells & chemo-resistance in aggressive rhabdomyosarcoma. How does this impact future treatments? PMID:42236477, Nat Commun 2026, @NatureComms #Medsky #Pharmsky #RNA #ASHG #ESHG 🧪
Continue reading on doi.orgYou might also wanna read

A hidden weakness in deadly cancers could lead to powerful new treatments
sciencedaily.com·4d ago

A hidden weakness in deadly cancers could lead to powerful new treatments
ScienceDaily·4d ago
Aneuploidy selects for the acquisition of driver genes in breast cancer
Nature Communications·1d ago
Promising pancreatic cancer drug may unlock new class of treatments targeting cancer's master switch
The article discusses a promising new drug that targets pancreatic tumors and may have revealed a "master switch" for cancer. The treatment
Retraction Note: NSD2 targeting reverses plasticity and drug resistance in prostate cancer
Nature Communications·9d ago
Study finds aging muscle may promote cancer growth, but exercise could restore protective function
Scientists discovered that aging muscle may contribute to cancer growth by releasing fewer extracellular vesicles—tiny particles cells use t
futurity.org·11d agoLab Study Finds Compound Stops 90% of Pancreatic Cancer Cell Migration
Researchers at Florida A&M University have discovered that compounds called polyisoprenylated cysteinyl amide inhibitors can stop 90% of pan
Lab Study Finds Compound Stops 90% of Pancreatic Cancer Cell Migration
Researchers at Florida A&M University have discovered that compounds called polyisoprenylated cysteinyl amide inhibitors can stop 90% of pan

Comments
Sign in to join the conversation.
No comments yet. Be the first.